VitaSpring Biomedical (OTCPK:VSBC) - Share price, News & Analysis

VSBC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

VSBC Stock Overview

VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine.

Rewards

Became profitable this year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

VitaSpring Biomedical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for VitaSpring Biomedical
Historical stock prices
Current Share Price	US$15.00
52 Week High	US$19.50
52 Week Low	US$10.00
Beta	1.74
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	21.95%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	3,471.43%

Shareholder Returns

	VSBC	US Biotechs	US Market
7D	0%	11.9%	4.0%
1Y	22.0%	-25.1%	-20.5%

Return vs Industry: VSBC exceeded the US Biotechs industry which returned -26.6% over the past year.

Return vs Market: VSBC exceeded the US Market which returned -20.8% over the past year.

Price Volatility

Is VSBC's price volatile compared to industry and market?
VSBC volatility
VSBC Average Weekly Movement	n/a
Biotechs Industry Average Movement	12.9%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.1%

Stable Share Price: Insufficient data to determine VSBC's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine VSBC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	n/a	Henry Kao	https://www.vitaspringbio.com

VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine. The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. in February 2020.

VitaSpring Biomedical Fundamentals Summary

How do VitaSpring Biomedical's earnings and revenue compare to its market cap?
VSBC fundamental statistics
Market Cap	US$3.10b
Earnings (TTM)	US$1.30m
Revenue (TTM)	US$6.57m

2,377x

P/E Ratio

471.7x

P/S Ratio

Is VSBC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
VSBC income statement (TTM)
Revenue	US$6.57m
Cost of Revenue	US$4.18m
Gross Profit	US$2.39m
Other Expenses	US$1.09m
Earnings	US$1.30m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	0.0063
Gross Margin	36.39%
Net Profit Margin	19.86%
Debt/Equity Ratio	0%

How did VSBC perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is VSBC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VSBC?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for VSBC. This is calculated by dividing VSBC's market cap by their current preferred multiple.
What is VSBC's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$3.10b

VSBC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	471.6x
Enterprise Value/EBITDA	2076.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does VSBC's PS Ratio compare to its peers?

VSBC PS Ratio vs Peers

The above table shows the PS ratio for VSBC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	36.9x

Forward PS

Price-To-Sales vs Peers: VSBC is expensive based on its Price-To-Sales Ratio (471.7x) compared to the peer average (36.9x).

Price to Earnings Ratio vs Industry

How does VSBC's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: VSBC is expensive based on its Price-To-Sales Ratio (471.7x) compared to the US Biotechs industry average (13.4x)

Price to Sales Ratio vs Fair Ratio

What is VSBC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VSBC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	471.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VSBC's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of VSBC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VSBC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VSBC's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VSBC's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is VitaSpring Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as VitaSpring Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Check out VitaSpring Biomedical's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access VitaSpring Biomedical's filings and announcements here.

Past Performance

How has VitaSpring Biomedical performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

78.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VSBC has high quality earnings.

Growing Profit Margin: VSBC became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: VSBC has become profitable over the past 5 years, growing earnings by 78.1% per year.

Accelerating Growth: VSBC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: VSBC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: VSBC's Return on Equity (69%) is considered outstanding.

Discover strong past performing companies

Financial Health

How is VitaSpring Biomedical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: VSBC's short term assets ($2.2M) exceed its short term liabilities ($381.1K).

Long Term Liabilities: VSBC's short term assets ($2.2M) exceed its long term liabilities ($424.9K).

Debt to Equity History and Analysis

Debt Level: VSBC is debt free.

Reducing Debt: VSBC has no debt compared to 5 years ago when its debt to equity ratio was 231.9%.

Debt Coverage: VSBC has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: VSBC has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Dividend

What is VitaSpring Biomedical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VSBC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VSBC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VSBC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VSBC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VSBC has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure

CEO

Henry Kao

2.42yrs

Tenure

Mr. Cheng-Hsiang Kao, also known as Henry, serves Chief Executive Officer of VitaSpring Biomedical Co. Ltd. since August 07, 2020. He is a Managing Director of Acro Biomedical Co., Ltd.Mr. Kao serves as a...

Leadership Team

Experienced Management: VSBC's management team is considered experienced (2.4 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/23 00:00
End of Day Share Price	2022/06/17 00:00
Earnings	2022/04/30
Annual Earnings	2022/01/31